ESSA PHARMA INC (EPIX)
CA29668H7085 - Common Stock
ESSA PHARMA INC
NASDAQ:EPIX (1/3/2025, 8:00:02 PM)
After market: 1.83 -0.03 (-1.61%)1.86
+0.03 (+1.64%)
Company Profile
ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 50 full-time employees. The company went IPO on 2021-02-22. The firm is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The firm is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
Company Info
ESSA PHARMA INC
999 West Broadway, Suite 720
Vancouver BRITISH COLUMBIA V5Z 1K5
P: 17783310962
CEO: David Parkinson
Employees: 50
Website: https://www.essapharma.com/
EPIX News
19 days ago - ESSA Pharma IncESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024/PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company that, prior to the discontinuation of its...
a month ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX). Such investors are...
a month ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX). Such investors are...
2 months ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX). Such investors are...
2 months ago - ESSA Pharma IncESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate CancerEfficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to...
4 months ago - ESSA Pharma IncESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO CongressCombination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion...
EPIX Twits
Here you can normally see the latest stock twits on EPIX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
